中国药物警戒 ›› 2026, Vol. 23 ›› Issue (5): 572-574.
DOI: 10.19803/j.1672-8629.20250733

• 安全与合理用药 • 上一篇    下一篇

利奈唑胺注射液致药物性肝损伤1例分析

汤柳1, 李洋2, 罗广文3#, 鲍引娣4,*   

  1. 1武汉大学人民医院药学部,湖北 武汉 430060;
    2武汉大学人民医院妇科,湖北 武汉 430060;
    3浙江大学医学院附属金华医院药学部,浙江 金华 321000;
    4武汉大学人民医院产科,湖北 武汉 430060
  • 收稿日期:2025-10-21 发布日期:2026-05-20
  • 通讯作者: *鲍引娣,女,博士,副主任医师,围产医学。E-mail：baoyindicomeon@126.com #为共同通信作者。
  • 作者简介:汤柳,女,博士,副主任药师,临床药学。
  • 基金资助:
    湖北省自然科学基金资助项目（2025AFB836）

One Case of Drug-Induced Liver Injury Caused by Linezolid Injection

TANG Liu1, LI Yang2, LUO Guangwen3#, BAO Yindi4,*   

  1. 1Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan Hubei 430060, China;
    2Department of Gynecology, Renmin Hospital of Wuhan University, Wuhan Hubei 430060, China;
    3Department of Pharmacy, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua Zhejiang 321000, China;
    4Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan Hubei 430060, China
  • Received:2025-10-21 Published:2026-05-20

PDF (PC)

36

摘要： 目的 探讨利奈唑胺注射液（以下简称“利奈唑胺”）致药物性肝损伤（Drug-Induced Liver Injury,DILI）的不良反应,为临床安全用药提供参考。方法 分析1例双胎妊娠患者中期引产后使用利奈唑胺联合注射用亚胺培南西司他丁钠抗感染致DILI的案例,以RUCAM量表量化药物与DILI的关联性,并结合国内外文献梳理其临床特征及治疗策略。结果 患者给予利奈唑胺联合亚胺培南西司他丁钠抗感染治疗3 d后,肝酶显著升高：丙氨酸氨基转移酶（ALT）212.24 U·L-1、天冬氨酸氨基转移酶（AST）222.76 U·L-1。立即停用利奈唑胺并启动保肝治疗后,肝酶下降明显。经RUCAM量表评分,判定该患者DILI与利奈唑胺的关联性为“很可能”。结论 临床应重视妊娠产后等特殊生理状态人群使用利奈唑胺时的DILI诱发风险,加强监测患者肝功能指标和相关症状体征,早期识别,减少DILI发生的风险。

关键词: 利奈唑胺注射液, 注射用亚胺培南西司他丁钠, 双胎妊娠, 药物性肝损伤, 药品不良反应

Abstract: Objective To analyze one case of drug-induced liver injury (DILI) caused by linezolid injection, and to provide references for safe medications. Methods One case of DILI caused by linezolid combined with imipenem/cilastatin sodium for anti-infection in a patient with twin pregnancy after second-trimester induction of labor was analyzed. The causal relationship between the administered drugs and DILI was quantitatively evaluated using the Roussel Uclaf Causality Assessment Method(RUCAM) scale. Additionally, related literature was reviewed to summarize the clinical characteristics of and therapeutic strategies for such cases. Results Three days after the patient received anti-infection treatment with linezolid combined with imipenem/cilastatin sodium, liver enzymes increased significantly, with alanine aminotransferase (ALT) reaching 212.24 U·L-1 and aspartate aminotransferase (AST) reaching 222.76 U·L-1. According to the score by the RUCAM scale, the causality between DILI and linezolid in this patient was determined as “probable”. After linezolid was immediately discontinued and hepatoprotective therapy was initiated, liver enzymes decreased significantly. Conclusion Clinicians should be alert for the risk of DILI induced by linezolid in special physiological populations such as those during the post-pregnancy and postpartum period. Liver function indicators and related symptoms of patients should be monitored closely to detect DILI early and reduce the risk.

Key words: Linezolid Injection, Imipenem and Cilastatin Sodium for Injection, Twin Pregnancy, Drug-Induced Liver Injury, Adverse Drug Reaction

中图分类号: